Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
United Therapeutics Corp Market Cap
From what 13 stock analysts predict, the share price for United Therapeutics Corp (UTHR) might increase by 4.43% in the next year. This is based on a 12-month average estimation for UTHR. Price targets go from $243 to $575. The majority of stock analysts believe UTHR is a hold. Please note analyst price targets are not guaranteed and could be missed completely.
About 13 Wall Street analysts have assignedUTHR 2 buy ratings, 6 hold ratings, and 5 sell ratings. This means that analysts expect United Therapeutics Corp to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on UTHR. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of UTHR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Hartaj Singh Oppenheimer | Outperform | $575 | Maintains | Aug 28, 2024 |
| Tiago Fauth Wells Fargo | Overweight | $380 | Maintains | Aug 20, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $400 | Reiterates | Aug 1, 2024 |
| Greg Harrison B of A Securities | Underperform | $280 | Maintains | Aug 1, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $400 | Maintains | Jul 25, 2024 |
| Terence Flynn Morgan Stanley | Equal-Weight | $321 | Downgrade | Jul 11, 2024 |
| Joseph Thome TD Cowen | Buy | $350 | Maintains | Jul 11, 2024 |
| Ashwani Verma UBS | Buy | $370 | Maintains | Jul 8, 2024 |
| Tiago Fauth Wells Fargo | Overweight | $350 | Maintains | Jun 12, 2024 |
| Jessica Fye JP Morgan | Overweight | $300 | Maintains | May 21, 2024 |
| Chris Shibutani Goldman Sachs | Neutral | $240 | Maintains | May 3, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $300 | Reiterates | May 2, 2024 |
| Hartaj Singh Oppenheimer | Outperform | $400 | Maintains | May 2, 2024 |
| Tiago Fauth Wells Fargo | Overweight | $325 | Maintains | Mar 7, 2024 |
| Liana Moussatos Wedbush | Outperform | $308 | Reiterates | Feb 22, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $300 | Reiterates | Feb 22, 2024 |
| Chris Shibutani Goldman Sachs | Neutral | $215 | Upgrade | Feb 12, 2024 |
| Roanna Ruiz Leerink Partners | Outperform | $330 | Initiates | Feb 5, 2024 |
| Liana Moussatos Wedbush | Outperform | $308 | Maintains | Nov 2, 2023 |
| Terence Flynn Morgan Stanley | Overweight | $314 | Maintains | Nov 2, 2023 |
When did it IPO
1999
Staff Count
1,168
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Market Cap
$15.24B
In 2023, UTHR generated $2.33B in revenue, which was a increase of 20.20% from the previous year. This can be seen as a signal that UTHR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - United Therapeutics Corporation released its 2024 Corporate Responsibility and Public Benefit Report, detailing FY 2023 progress and financial performance in advancing patient interests.
Why It Matters - United Therapeutics' 2024 Corporate Responsibility Report highlights its financial performance and commitment to stakeholders, signaling potential growth and sustainability, which can influence investor confidence.
Fri, 30 Aug 2024
Sentiment - POSITIVE
Source - FXEmpire
Summary - United Therapeutics Corporation (UTHR) shares are rising due to revenue growth and a recent regulatory victory.
Why It Matters - Revenue growth indicates strong performance, while a regulatory win boosts future prospects, making United Therapeutics more attractive for investment and likely increasing share value.
Fri, 30 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - United Therapeutics (UTHR) recently reported earnings, with investors now considering potential future developments for the stock.
Why It Matters - Upcoming earnings reports can significantly impact stock prices. Investors will assess performance trends to gauge future growth potential and make informed decisions.
Wed, 28 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - United Therapeutics Corporation (Nasdaq: UTHR) will present updates at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, in New York City.
Why It Matters - Executive presentations at investor conferences provide insights into company operations and strategy, influencing investor sentiment and stock performance.
Mon, 19 Aug 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - United Therapeutics Corporation shows strong growth with Q2 FY'24 earnings up, especially in Tyvaso. Share buybacks initiated; aiming for $3B revenue run rate by FY'25, with a $400/share valuation.
Why It Matters - United Therapeutics' strong Q2 growth, share buybacks, and projected revenue increase signal robust financial health and potential for stock appreciation, making it an attractive investment opportunity.
Fri, 16 Aug 2024
Sentiment - POSITIVE
Source - Investors Business Daily
Summary - Top five biotech stocks share strong ratings, indicating positive investor sentiment and potential growth in the sector.
Why It Matters - Strong ratings for the top biotech stocks indicate robust performance and potential for growth, attracting investor interest and shaping market trends.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
